{"id":"NCT04247074","sponsor":"Galderma R&D","briefTitle":"Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-02-10","primaryCompletion":"2020-10-02","completion":"2021-02-26","firstPosted":"2020-01-29","resultsPosted":"2023-09-06","lastUpdate":"2023-09-06"},"enrollment":413,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Glabellar Frown Lines (GL)","Lateral Canthal Lines (LCL)"],"interventions":[{"type":"BIOLOGICAL","name":"botulinum toxin neuromodulator","otherNames":["QM1114-DP"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"QM1114-DP in the LCL + Placebo in the GL","type":"EXPERIMENTAL"},{"label":"Placebo in the LCL and GL","type":"PLACEBO_COMPARATOR"},{"label":"Placebo in the LCL + QM1114-DP in the GL","type":"EXPERIMENTAL"},{"label":"QM1114-DP in the LCL + GL","type":"EXPERIMENTAL"}],"summary":"This study is designed to evaluate the safety and efficacy of a single dose of QM1114-DP for the treatment of moderate to severe LCL and moderate to severe GL, alone or in combination.","primaryOutcome":{"measure":"Percentage of Subjects With a â‰¥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown","timeFrame":"Month 1","effectByArm":[{"arm":"Placebo in the LCL and GL","deltaMin":0,"sd":null},{"arm":"Placebo in the LCL + QM1114-DP in the GL","deltaMin":75,"sd":null},{"arm":"QM1114-DP in the LCL + GL (GL Data)","deltaMin":78,"sd":null}],"pValues":[{"comp":"OG000 vs OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":12,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":123},"commonTop":["COVID-19","Headache","Injection site bruising","Eyelid ptosis","Injection site pain"]}}